Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of BAY 2927088 in HER2-activating mutation-positive advanced solid tumors
CTR20250361Phase 2Active
- Sponsor
- Bayer
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sevabertinib in Nonhematologic neoplasms, colorectal cancer (CRC), biliary cancer, bladder cancer, urethral cancer, sponsored by Bayer. Started Feb 2025; status: active.
02
Drugs
sevabertinib
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)biliary cancerbladder cancerurethral cancer
Beyond the preview
Go deeper on CTR20250361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250361.